Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical therapies, and injectable biologics. New topical agents such as Arcutis’s Zoryve and Incyte’s Opzelura are expanding options for mild to moderate AD. For moderate to severe AD, the expanding treatment armamentarium includes IL-13 inhibitors (e.g., Sanofi / Regeneron’s Dupixent, LEO Pharma’s Adbry, Eli Lilly / Almirall’s Ebglyss), systemic JAK inhibitors (e.g., Pfizer’s Cibinqo, AbbVie’s Rinvoq), and an IL-31 inhibitor (Galderma’s Nemluvio). In December 2024, the FDA approved Organon’s topical Vtama for mild, moderate, and severe AD. Although Dupixent has largely established its position in AD treatment, payer policies affecting more recently approved therapies will influence physician prescribing and patient access to newer therapies.
QUESTIONS ANSWERED
- What are the current prescribing practices for AD, and how are they impacted by payer policy?
- What are dermatologists’ and payers’ opinions of recently approved therapies, and how has their availability for AD impacted physician prescribing and payer reimbursement?
- How will dermatologists’ prescribing of established agents by line of therapy shift as these new agents are incorporated into the treatment algorithm?
- As systemic JAK inhibitors are granted label expansions for AD, what do payers say about the use of indication-based formularies?
- What are payers’ and dermatologists’ perspectives on promising emerging agents such as Kyowa Kirin / Amgen’s rocatinlimab, Sanofi’s amlitelimab, and Otsuka / Acrotech’s difamilast?
CONTENT HIGHLIGHTS
Geography: United States
Primary Research: Survey of 100 U.S. dermatologists. Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Fingertip Formulary: Formulary coverage by commercial plans covering 164.3 million lives nationally.
Real-world data: U.S. pharmacy and medical claims data
Key Drugs Covered: Adbry, Cibinqo, Dupixent, Eucrisa, Opzelura, Rinvoq, Ebglyss, Nemluvio, Zoryve, Vtama, Rocatinlimab, Amlitelimab, Difamilast.
PRODUCT DESCRIPTION
Leveraging Clarivate’s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:
- Identify and learn how to overcome roadblocks to market access to best position your brand.
- Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.
- Evaluate competitor strategies for securing favorable market access terms.
